[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-proliferative-diabetic-retinopathy-npdr\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-proliferative-diabetic-retinopathy-npdr":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100620196","phase-2-single-site-pilot-study-evaluating-the-effect-of-qls-111-ophthalmic-solution-on-posterior-perfusion-and-vessel-dilation-100620196",false,"NCT07354477","Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation","An Exploratory, Pilot, Single-site Study to Evaluate the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation","(PENGUIN)","Inclusion Criteria:\n\n* Diagnosis of mild to moderate OAG, mild to moderate NTG, or stable NPDR in at least one eye.\n* Corrected visual acuity in each eye +1.0 logMAR or better by early treatment diabetic retinopathy study (ETDRS) in each eye (equivalent to 20\u002F200).\n* Able and willing to give signed informed consent and follow study instructions.\n\nExclusion Criteria:\n\n* History of active ocular disease other than mild to moderate OAG, mild to moderate NTG, or stable NPDR.\n* Patient is using more than 1 ocular hypotensive topical medication for intraocular pressure (IOP) control (prior MIGS and\u002For laser trabeculoplasty to control IOP is allowed if done at least 3 months from Screening (Visit 1).\n* Use of TO β-blockers (i.e. timolol) within 3 months prior to Screening.\n* Is noncompliant with current ocular anti-hypotensive medications and\u002For unwilling to be compliant throughout the study.\n* Clinically significant severe retinal disease in either eye that will require treatment during the study (e.g., proliferative diabetic retinopathy, exudative, or severe non-exudative macular degeneration). NOTE: background diabetic retinopathy (BDR) as required for the NPDR subjects is allowed if in the Investigator's opinion the BDR is stable and is expected to remain stable during the duration of the study.\n* Anti-VEGF or TO steroid treatment within 3 months prior to Screening or expected treatment while participating in this study. Prior diabetic macular edema (DME) history is allowed if adequately controlled with treatment (anti-VEGFs and steroids not within last 3 months prior to Screening), regimen is stable, and not expected to change during the study. - Corneal pathologic changes preventing reliable measurement (e.g., scarring, opacity, edema, and bullae) in either eye that would inhibit accurate IOP measurements.\n* Previously diagnosed, clinically significant systemic or psychiatric disease (e.g., myasthenia gravis, hepatic, renal, endocrine, pulmonary, or cardiovascular disorders) which might compromise the study results or subject safety. For the purpose of this study previously diagnosed, clinically significant renal disease that should be excluded from enrollment will be defined as Stages 3-5 kidney disease and\u002For an estimated glomerular filtration rate (eGFR) of ≤59.\n* Use of calcium channel blockers.\n* Labile hypertension and\u002For hypotension that is inadequately controlled,","ALL","18 Years",{"count":20,"type":21},14,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG",[27,28,29],"Non-proliferative Diabetic Retinopathy (NPDR)","Open-angle Glaucoma (OAG)","Normal Tension Glaucoma (NTG)",[31,32,33],"glaucoma","diabetic retinopathy","vessel dilation","RECRUITING","2026-02-21",{"date":37,"type":38},"2026-02-24","ACTUAL",{"date":40,"type":38},"2026-02-20",{"date":42,"type":21},"2026-06",{"name":44,"class":45},"Qlaris Bio, Inc.","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100611135","phase-2-efficacy-and-safety-of-ginkgo-biloba-extract-egb761-in-patients-with-diabetic-retinopathy-100611135","NCT07236645","Efficacy and Safety of Ginkgo Biloba Extract EGb761® in Patients With Diabetic Retinopathy","Efficacy and Safety of Ginkgo Biloba Extract EGb761® in Patients With Diabetic Retinopathy: A Single-Center, Open-Label, Parallel-Group Controlled Trial","Inclusion Criteria:\n\n1. Aged 18 years or older, regardless of gender;\n2. Meeting the diagnostic criteria for diabetes mellitus with glycated hemoglobin (HbA1c) ≤13%;\n3. Having a diabetes duration ≥5 years without diagnosed diabetic retinopathy or, according to the DR staging criteria proposed by the Group of Fundus Diseases, Ophthalmology Society of Chinese Medical Association in 2014, having at least one eye diagnosed with Stage I or II non-proliferative diabetic retinopathy (NPDR) without concomitant diabetic macular edema (DME);\n4. Voluntarily signing the informed consent form.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women.\n2. Poorly controlled hypertension (defined as ≥180\u002F100 mmHg).\n3. Patients with coexisting ocular pathologies, such as glaucoma or cataract.\n4. Patients with severe impairment of cardiac, pulmonary, hepatic, or renal function, or coagulation disorders, e.g., alanine aminotransferase (ALT) ≥2 times the upper limit of normal (ULN), aspartate aminotransferase (AST) ≥2 ULN, total bilirubin (BIL) ≥1.5 ULN, or estimated glomerular filtration rate (eGFR) ≤30 mL\u002Fmin\u002F1.73 m².\n5. Patients with comorbid psychiatric or neurological disorders.\n6. Patients with a known allergy to any component of the investigational product.\n7. Patients who received Ginkgo biloba extract treatment within the past 12 months.\n8. Patients with a history of intraocular treatments, such as panretinal photocoagulation (PRP), and\u002For anti-vascular endothelial growth factor (VEGF) therapy, and\u002For ocular surgery.\n9. Patients with a history of cardiovascular events or conditions requiring long-term anticoagulation therapy, such as deep vein thrombosis, pulmonary embolism, atrial fibrillation, or cardiac valve replacement.\n10. Any contraindication that, in the investigator's judgment, could limit clinical assessment or treatment.\n11. Concurrent participation in any other clinical trial.\n12. Patients deemed by the investigator to be unsuitable for inclusion in this study.",{"count":55,"type":21},200,[24],"This study is a single-center, open-label, parallel-controlled trial, scheduled to commence in October 2025 at the outpatient and inpatient departments of Shanghai General Hospital. Eligible patients with diabetes mellitus and\u002For non-proliferative diabetic retinopathy (NPDR), who meet the inclusion and exclusion criteria, will be recruited. General and disease-related information will be collected. All eligible participants will be required to voluntarily sign an informed consent form after fully understanding and accepting the study. Successfully enrolled subjects will be randomly assigned to the Ginaton group or the conventional treatment group, and will receive the corresponding interventions as specified in the study protocol. Follow-up assessments will include blood pressure, blood glucose, glycated hemoglobin, blood lipids, hemorheological parameters, glomerular filtration rate, microalbuminuria, nerve conduction velocity by electromyography, visual acuity, wide-field fundus photography, quality of life (SF-36 questionnaire), and adverse events. The study aims to evaluate the efficacy and safety of ginkgo biloba extract tablet in preventing the development of diabetic retinopathy in patients with long-standing diabetes, as well as in treating patients with mild to moderate NPDR without concomitant diabetic macular edema (DME).",[27],"NOT_YET_RECRUITING","2025-11-14",{"date":62,"type":38},"2025-11-19",{"date":64,"type":21},"2025-11-20",{"date":66,"type":21},"2028-12-31",{"name":68,"class":69},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","OTHER",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":22,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100608227","early-phase-1-a-preliminary-exploratory-clinical-trial-to-evaluate-the-efficacy-of-npdr-01-eye-drops-in-the-treatment-of-non-proliferative-diabetic-retinopathy-100608227","NCT07198815","A Preliminary Exploratory Clinical Trial to Evaluate the Efficacy of NPDR-01 Eye Drops in the Treatment of Non-Proliferative Diabetic Retinopathy","Inclusion Criteria:\n\n1.1. Patients aged 18 to 75 years diagnosed with type 1 or type 2 diabetes mellitus, with non-proliferative diabetic retinopathy (NPDR) confirmed by a qualified ophthalmologist. NPDR diagnosis must be based on current standard fundus examination or retinal photography and should meet the International Clinical Diabetic Retinopathy Disease Severity Scale, with the presence of microaneurysms.\n\n1.2. Willing and able to comply with study procedures and provide informed consent: Subjects must voluntarily participate in the study, sign the informed consent form, and fully understand the study objectives, potential drug risks, and research procedures. There should be no other ocular diseases causing retinal neovascularization.\n\n1.3. No known significant media opacities that would interfere with fundus image acquisition.\n\n1.4. No history of retinal laser photocoagulation, and no anticipated laser treatment within the next 6 months.\n\n1.5. No history of intravitreal injection therapies, and no anticipated intravitreal treatments within the next 6 months.\n\n1.6. No diabetic macular edema (DME) as defined by central retinal thickness on OCT: \\\u003C290 μm for females and \\\u003C305 μm for males (or \\\u003C305 μm for females and \\\u003C320 μm for males, depending on the criteria used).\n\n1.7. Clinical fundus examination and ultra-widefield retinal photography show DR changes milder than early proliferative DR (PDR).\n\n1.8. No history of ocular surgery. 1.9. Diabetes history: Duration of diabetes ≥ 1 year; glycemic control with HbA1c ≤ 10%.\n\n1.10. Visual acuity requirement: Best-corrected visual acuity (BCVA) must be better than 20\u002F400, to ensure reliable assessment of drug efficacy.\n\nExclusion Criteria:\n\n2.1. Age Restrictions: Subjects younger than 35 years or older than 75 years. 2.2. Severe Ocular Complications: Subjects whose diabetic retinopathy has progressed to proliferative diabetic retinopathy (PDR) or who present with clinically significant macular edema (CSME). This includes vitreous hemorrhage, retinal detachment, or other acute complications. Also excluded are subjects with severe optic nerve damage or glaucoma (intraocular pressure \\> 21 mmHg).\n\n2.3. Poor Diabetes Control: Subjects with HbA1c \\> 10%, or with highly fluctuating blood glucose levels that may interfere with efficacy evaluation.\n\n2.4. Other Ocular Diseases: Presence of age-related macular degeneration (AMD), retinal vascular occlusion, retinal infections, or other significant ocular pathologies. Also excluded are those with corneal diseases, severe conjunctivitis, or dry eye syndrome that may affect topical ocular drug administration.\n\n2.5. History of Ocular Surgery or Treatments: Subjects who received intraocular injections (e.g., anti-VEGF agents) or retinal laser therapy within the past 6 months. Also excluded are those who recently underwent cataract surgery or other retinal-related surgeries.\n\n2.6. Other Health Conditions: Subjects with abnormal liver function, disorders in ketone body metabolism, or those with serious systemic diseases that may interfere with treatment (e.g., acute heart disease, liver disease, renal failure). History of cancer or current malignancy, or any major illness affecting drug metabolism or immune function.\n\n2.7. Drug Allergy History: Known allergy or hypersensitivity to the study drug or any of its components (e.g., drug carriers, excipients).\n\n2.8. Concomitant Medications: Use of antiplatelet agents (e.g., aspirin, clopidogrel) or anticoagulants (e.g., warfarin, rivaroxaban). Also excluded are those with poorly controlled hypertension, or those who have recently undergone major changes in antihypertensive therapy.\n\n2.9. Pregnant or Lactating Women: Pregnant or breastfeeding women are excluded due to potential drug transmission through the placenta or breast milk that could affect the fetus or infant.\n\n2.10. Other: Subjects who are unwilling or unable to comply with study procedures or follow-up. Any other individuals deemed unsuitable for the study at the discretion of the investigator.","35 Years","75 Years",{"count":79,"type":21},10,[81],"EARLY_PHASE1","This study aims to explore the preliminary clinical efficacy and safety of NPDR-01 eye drops in patients with non-proliferative diabetic retinopathy (NPDR).",[27,84,85,86],"Diabetic Retinal Microangiopathy","Retinal Microaneurysms","Diabetic Retinopathy",[88,89,90],"Diabetic retinopathy","Non-proliferative diabetic retinopathy","Retinal microaneurysms","2025-09-22",{"date":93,"type":38},"2025-09-30",{"date":95,"type":21},"2025-12-01",{"date":97,"type":21},"2026-12-01",{"name":99,"class":69},"Sichuan Academy of Medical Sciences"]